Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pylori

Scientia Pharmaceutica

Volumn 79, Issue 3, 2011, Pages 673-694

  Arora, Saahil ^a   Gupta, Sankalp ^a   Narang, Raj K ^a   Budhiraja, Ramji D ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Box behnken design; Factorial design; Helicobacter pylori; Mucopenetration; Stomach specific delivery system

Indexed keywords

ALGINIC ACID; AMOXICILLIN; CHITOSAN; NANOPARTICLE; POLYMER; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; HELICOBACTER PYLORI; IN VITRO STUDY; IN VIVO STUDY; MALE; MUCOADHESION; MUCOPENETRATING DELIVERY SYSTEM; NONHUMAN; PARTICLE SIZE; PH; RAT; STOMACH MUCOSA; SURFACE PROPERTY;

EID: 80051719667     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1011-05     Document Type: Article

References (52)

1. Murakami K, Okimoto T, Kodama M, Sato R, Miyajima H, Ono M, Inoue K, Watanabe K, Otsu S, Fujioka T. Comparison of Amoxicillin-Metronidazole Plus Famotidine or Lansoprazole for Amoxicillin-Clarithromycin-Proton Pump Inhibitor Treatment Failures for Helicobacter pylori Infection. Helicobacter. 2006; 11: 436-440. doi: 10.1111/j.1523-5378.2006.00435.x
2. Cooreman MP, Krausgrill P, Hengela KJ. Local gastric & serum Amoxicillin concentration after different oral application forms. Antimicrob Agents Chemother. 1993; 37: 1506-1509. PMid:8363383
3. Endo H, Yoshida H, Ohmi N, Ohta K, Higuchi S. Localization of [14C] amoxicillin in rat gastric tissue when administered with lansoprazole and clarithromycin. J Antimicrob Chemother. 2001; 48: 923-926. doi:10.1093/jac/48.6.923
4. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997; 39: 5-12. doi:10.1093/jac/39.1.5
5. Sahasathian T, Kerdcholpetch T, Chanweroch A, Praphairaksit N, Suwonjandee N, Muangsin N. Sustained Release of Amoxicillin from Chitosan Tablets. Arch Pharmacal Res. 2007; 30: 526-531. doi:10.1007/BF02980229
6. Kotwal A, Pathak AK. Formulation and evaluation of intragastric buoyant tablets of amoxicillin trihydrate. Int J Pharm Life Sci. 2011; 2: 546-550.
7. Pandit V, Suresh S, Joshi H. Gastroretentive drug delivery system of amoxycillin: Formulation and in vitro evaluation. Int J Pharm Bio Sci. 2010; 1: 1-10.
8. Rao KM, Gnanaprakash K, Chandra Sekhar KB, Chety CM. Formulation and in-vitro characterization of floating microspheres of amoxycillin trihydrate against H. pylori. J Pharm Res. 2011; 4: 836-840.
9. Badhan AC, Mashru RC, Shah PP, Thakkar AR, Dobaria NB. Development and Evaluation of Sustained Release Gastroretentive Minimatrices for Effective Treatment of H. pylori Infection. AAPS PharmSciTech. 2009; 10: 459-467. doi:10.1208/s12249-009-9231-4
10. Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm. 2000; 210: 45-49. doi:10.1016/S0378-5173(00)00567-6
11. Nagahara N, Akiyama Y, Tada M, Nakao M, Kitano M, Ogawa Y. Mucoadhesive microspheres containing amoxycillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother. 1998; 42: 2492-2494. PMid:9756746
12. Lin YH, Chang CH, Wu YS, Hsu YM, Chiou SF, Chen YJ. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials. 2009; 30: 3332-3342. doi:10.1016/j.biomaterials.2009.02.036
13. Patel JK, Patel MM. Stomach Specific Anti-Helicobacter Pylori Therapy: Preparation and Evaluation of Amoxicillin Loaded Chitosan Mucoadhesive Microspheres. Curr Drug Deliv. 2007; 4: 41-50. doi:10.2174/156720107779314811
14. Ishak RAH, Awad GAS, Mortada ND, Nour SAK. Preparation, in vitro and in vivo evaluation of stomach specific metronidazole loaded alginate beads as local antihelicobacter pylori therapy. J Control Release. 2007; 119: 207-214. doi:10.1016/j.jconrel.2007.02.012
15. Siddalingam P, Mishra RB. Preparation and in vitro characterization of gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharm. 2007; 57: 413-427. doi:10.2478/v10007-007-0033-5
16. Wang J, Tauchi Y, Deguchi Y, Morimoto K, Tabata Y, Ikada Y. Positively Charged Gelatin Microspheres as Gastric Mucoadhesive Drug Delivery System for Eradication of H. pylori. Drug Deliv. 2000; 7: 237-243. doi:10.1080/107175400455173
17. Liu Z, Lua W, Qianb L, Zhanga X, Zenga P, Pana J. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J Control Release. 2005; 102: 135-144. doi:10.1016/j.jconrel.2004.06.022
18. Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using Cholestyramine. Drug Delivery. 2003; 10: 151-160. doi:10.1080/713840399
19. Umamaheshwari RB, Ramteke S, Jain NK. Anti-Helicobacter Pylori Effect of Mucoadhesive Nanoparticles Bearing Amoxicillin in Experimental Gerbils Model. AAPS PharmSciTech. 2004; 5: 1-9. doi:10.1208/pt050225
20. Lehr CM, Bodde HE, Bouwstra JA, Junginger HE. A surface energy analysis of mucoadhesion. II. Prediction of mucoadhesive performance by spreading coefficients. Eur J Pharm Sci. 1993; 1: 19-30. doi:10.1016/0928-0987(93)90014-2
21. Algood HMS, Cover TL. Helicobacter pylori Persistence: an Overview of Interactions between H. pylori and Host Immune Defenses. Clin Microbiol Rev. 2006; 19: 597-613. doi:10.1128/CMR.00006-06
22. Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, Kelly CP, Ewoldt RH, McKinley GH, So P, Erramilli S, Bansil R. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A. 2009; 106: 14321-14326. doi:10.1073/pnas.0903438106
23. Cuña M, Alonso MJ, Torres D. Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxicillin-resin complexes for drug delivery to the gastric mucosa. Eur J Pharm Biopharm. 2001; 51: 199-205. doi:10.1016/S0939-6411(01)00124-2
24. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009; 61: 158-171. doi:10.1016/j.addr.2008.11.002
25. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials. 2009; 30: 2591-2597. doi:10.1016/j.biomaterials.2008.12.076
26. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, Zeitlin P, Boyle MP, Fu J, Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A. 2009; 106: 19268-19273. doi:10.1073/pnas.0905998106
27. Zhang X, Zhang H, Wu Z, Wang Z, Niu H, Li C. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm. 2008; 68: 526-534. doi:10.1016/j.ejpb.2007.08.009
28. Dawson M, Krauland E, Wirtz D, Hanes J. Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Progr. 2004; 20: 851-857. doi:10.1021/bp0342553
29. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm. 2008; 68: 513-525. doi:10.1016/j.ejpb.2007.09.009
30. U.S. Department of Health and Human Services. FDA guidance of industry, ICH Q8 pharmaceutical development. FDA/CDER/CBER, http://www.fda.gov/CbER/gdlns/ichq8pharm.pdf (2010) Accessed 15 May 2010.
31. Govender S, Pillay V, Chetty DJ, Essack SY, Dangor CM, Govender T. Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres. Int J Pharm. 2005; 306: 24-40. doi:10.1016/j.ijpharm.2005.07.026
32. Ahmed SZ, Omaima AS, Mohammed AH, Nagia AM, Muhammad JH, Mansoor AK. Quality by design: Understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int J Pharm. 2007; 332: 55-63 doi:10.1016/j.ijpharm.2006.09.060
33. Box-Behnken designs. http://www.itl.nist.gov/div898/handbook/pri/section3/pri3362.htm Accessed 4 Feb 2010.
34. Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics. 1960; 2: 455-475. doi:10.2307/1266454
35. Calvo P, Lopez CR, Jato JLC, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Poly Sci. 1997; 63: 125-132. doi:10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
36. Douglas KL, Tabrizian MJ. Effect of experimental parameters on the formation of alginate-chitosan nanoparticles and evaluation of their potential application as DNA carrier. J Biomater Sci Polymer Ed. 2005; 16: 43-56. doi:10.1163/1568562052843339
37. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Delivery. 2001; 47: 83-97. doi:10.1016/S0169-409X(00)00123-X
38. Simsek-Ege FA, Bond GM, Stringer J. Polyelectrolyte complex formation between alginate and chitosan as a function of pH. J Appl Poly Sci. 2003; 88: 346-351. doi:10.1002/app.11989
39. Chopra S, Motwani SK, Iqbal Z, Talegaonkar S, Ahmad FJ, Khar RK. Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. Eur J Pharm Biopharm. 2007; 67: 120-131. doi:10.1016/j.ejpb.2006.12.013
40. Torrado S, Prada P, Torre PM, Torrado S. Chitosan-poly (acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention. Biomaterials. 2004; 25: 917-923. doi:10.1016/S0142-9612(03)00579-9
41. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Rel. 2001; 70: 399-421. doi:10.1016/S0168-3659(00)00361-8
42. Deacon MP, McGurk S, Roberts CJ, Williams PM, Tendler SJ, Davies MC, Davis SS, Harding SE. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J. 2000; 348: 557-563. doi:10.1042/0264-6021:3480557
43. Chellat F, Tabrizian M, Dumitriu S, Chornet E, Magny P, Rivard CH, Yahia L. In vitro and in vivo biocompatibility of chitosan-xanthan polyionic complex. J Biomed Mater Res. 2000; 51: 107-116. doi:10.1002/(SICI)1097-4636(200007)51:1<107::AID-JBM14>3.0.CO;2-F
44. Roula BQ, Mansoor MA. Synthesis of a fluorescent chitosan derivative and its application for the study of chitosan-mucin interactions. Carbohyd Polymer. 1999; 38: 99-107. doi:10.1016/S0144-8617(98)00109-X
45. Candioti LV, Robles JC, Mantovani VE, Goicoechea HC. Multiple response optimization applied to the development of a capillary electrophoretic method for pharmaceutical analysis. Talanta. 2006; 69: 140-147. doi:10.1016/j.talanta.2005.09.021
46. McCarron PA, Woolfson DA, Keating SM. Response surface methodology as a predictive tool for determining the effects of preparation conditions on the physicochemical properties of poly (isobutylcyanoacrylate) nanoparticles. Int J Pharm. 1999; 193: 37-47. doi:10.1016/S0378-5173(99)00311-7
47. Chopra S, Patil GV, Motwani SK. Release modulating hydrophilic matrix systems of losartan potassium: Optimisation of formulation using statistical experimental design. Eur J Pharm Biopharm. 2007; 66: 73-82. doi:10.1016/j.ejpb.2006.09.001
48. Ramteke S, Ganesh N, Bhattacharya S, Jain NK. Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori. J Drug Target. 2009; 17: 225-234. doi:10.1080/10611860902718649
49. De S, Robinson D. Polymer relationships during preparation of chitosan-alginate and poly-L-lysine-alginate nanospheres. J Control Rel. 2003; 89: 101-112. doi:10.1016/S0168-3659(03)00098-1
50. Ramteke S, Jain NK. Clarithromycin and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori. J Drug Target. 2008; 16: 65-72. doi:10.1080/10611860701733278
51. Elhady SSA, Mortada ND, Awad GAS, Zaki NM, Taha RA. Development of in situ gelling and mucoadhesive Mebeverine hydrochloride solution for rectal Administration. Saudi Pharm J. 2003; 11 (Suppl 4): 159-171.
52. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of Antituberculosis drugs. Eur J Pharm Sci. 2007; 32: 140-150. doi:10.1016/j.ejps.2007.06.006